Opinion|Videos|January 17, 2025

A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2

In the second part of a two-part interview on the recently published appropriate use criteria for brain positron emission tomography (PET) for patients with mild cognitive impairment (MCI), Phillip Kuo, M.D. discusses clinical cases involving the use of amyloid and tau PET imaging.

“I like to say that amyloid (PET) is necessary for the diagnosis of Alzheimer’s disease but not sufficient,” noted Phillip Kuo, M.D., during a recent interview to discuss the recently released appropriate use criteria for amyloid and tau positron emission tomography (PET) in patients with mild cognitive impairment (MCI).

Related to this article

August 31st, 2026

Molecular Imaging in Focus: Emerging PET/CT Radiotracer 124I-Evuzamatide Offers Promise for Detection of Cardiac Amyloidosis

In a recent episode of our Molecular Imaging in Focus series, Sharmila Dorbala, MD, MPH, discusses phase 3 study findings on the use of the PET/CT radiotracer 124I- evuzamatide for overall detection of cardiac amyloidosis as well as the subtypes light-chain amyloidosis (AL) and transthyretin amyloidosis (ATTR) cardiac amyloidosis.

September 20th, 2026

Radiology Roundup of FDA News: September 13 — September 19

Catch up on a variety of FDA news in radiology from the past week.

September 19th, 2026

Diagnostic Imaging’s Weekly Scan: September 13 — September 19

Catch up on the top radiology content of the past week.

September 18th, 2026

FDA Clears Software That Combines MRI Enhancement of PET Imaging with Automated Quantification of Amyloid and Tau PET

Incorporating structural MRI to improve PET imaging resolution, the MICSI-PET software also offers automated Centiloid quantification from amyloid PET scans.

September 14th, 2026

Molecular Imaging in Focus: Can the Newly FDA-Approved PET Agent Floretyrosine F18 Have an Impact for Glioma Imaging?

In a recent episode of our Molecular Imaging in Focus series, Thomas Hope, MD, discussed challenges with conventional imaging for gliomas and the potential of the newly FDA-approved PET agent floretyrosine F18 (18F-FET) for differentiating between glioma progression and treatment-related effects.

September 12th, 2026

Diagnostic Imaging's Weekly Scan: September 6 — September 12

Catch up on the top radiology content of the past week.

September 10th, 2026

Video: Stamatia Destounis, MD, FACR, Discusses Key Changes for the Updated BI-RADS System

In a recent interview, Stamatia Destounis, MD, FACR, shared her perspective on recent changes to the BI-RADS system, offering insights on contrast-enhanced mammography, reporting changes for breast MRI and ultrasound, and the importance of auditing for BI-RADS category 3 assessments.

September 9th, 2026

Can MRI-Guided Reconstruction Improve Assessment of Amyloid Brain PET Scans?

New research demonstrates significantly higher specificity and inter-reader agreement with MRI-guided reconstruction in comparison to standard ordered-subset expectation-maximization (OSEM) reconstruction of PET imaging for amyloid assessment.